The drug is being developed in multiple diseases driven by allergic and other Type 2 inflammation. Credit: BruceBlaus.

Sanofi’s Dupixent has been approved by the European Commission (EC) as an add-on maintenance treatment for severe asthma in adults and adolescents.

The indication includes patients with Type 2 inflammation characterised by increased blood eosinophils or fractional exhaled nitric oxide (FeNO) that did not experience adequate control with high-dose inhaled corticosteroid (ICS) plus maintenance treatments.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Dupixent is a human monoclonal antibody (mAb) designed to inhibit the signalling of interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins involved in Type 2 inflammation, which is known to cause specific types of asthma and other allergic diseases.

The inhibition is intended to reduce Type 2 inflammatory biomarkers, including FeNO, immunoglobulin E (IgE) and eotaxin-3 (CCL26).

The EC’s decision was based on results from the LIBERTY ASTHMA programme, which involved a total of 2,888 participants across the Phase III QUEST and VENTURE studies and a Phase IIb study.

“Dupixent not only reduced exacerbations and oral corticosteroid use, but it also improved lung function and patients’ overall quality of life.”

Involving 1,902 patients with persistent asthma, QUEST assessed the ability of Dupixent plus standard-of-care therapy to minimise severe exacerbations and improve lung function.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

VENTURE enrolled 210 subjects with severe oral corticosteroid-dependent asthma and assessed if Dupixent plus standard-of-care therapy could cut the use of maintenance oral corticosteroids.

The Phase IIb trial investigated the effect of the combination on lung function. It enrolled a total of 776 adult patients suffering from moderate-to-severe asthma.

Sanofi research and development (R&D) head John Reed said: “In clinical trials, Dupixent not only reduced exacerbations and oral corticosteroid use, but it also improved lung function and patients’ overall quality of life.

“Dupixent offers a new treatment option for those who remain inadequately controlled with current medications, including those dependent on oral corticosteroids, which may have potentially serious side effects when used chronically.”

In partnership with Regeneron, the drug is being assessed in multiple diseases driven by allergic and other Type 2 inflammation.

Dupixent obtained the US Food and Drug Administration (FDA) approval as an add-on maintenance treatment moderate-to-severe asthma in October last year.